DesignMedix, Inc develops drugs to overcome drug resistance in multiple diseases, and has a malaria drug nearly ready for human trials.
DesignMedix develops drugs to overcome drug resistance in multiple diseases that kill millions of people each year. Drug resistance is one of the top threats to human health. Leveraged by grants, most recently an award of $3 million from NIH, DesignMedix has efficiently used angel investment to develop a novel drug to cure malaria that is ready for human trials soon. Other projects address reversing drug resistance in bacterial diseases.